1. <nobr id="heyne"></nobr>
          <nobr id="heyne"></nobr>

          <form id="heyne"><th id="heyne"></th></form>

          1. Continual Improvement of the Reliability of Next-Generation Sequencing-Based ctDNA Analysis: A Long-Term Comparison of ctDNA Detection in China
            Rongxue Peng 1, Rui Zhang 1, Jinming Li

            These data demonstrated that the performance of individual Chinese laboratories for NGS-based ctDNA analysis continuously improved over time with participation in PT schemes. However, further care must also be taken in standardized operations and validations.

            Clin Chem. 2022 Jun 10;hvac055. 

            Analysis of KRAS, NRAS, and BRAF Mutations, Microsatellite Instability, and Relevant Prognosis Effects in Patients With Early Colorectal Cancer: A Cohort Study in East Asia
            Yang Li, 1 , ? Jun Xiao,corresponding author 1 , * , ? Tiancheng Zhang, 1 Yanying Zheng, 2 and Hailin Jin

            Patients with ECRC might benefit from KRAS mutation testing but not from postoperative chemotherapy.

            Front Oncol. 2022; 12: 897548.

            Molecular Targets in Lung Cancer: Study of the Evolution of Biomarkers Associated with Treatment with Tyrosine Kinase Inhibitors—Has NF1 Tumor Suppressor a Key Role in Acquired Resistance?
            Bego?a O Alen 1 2, Lara S Estévez-Pérez 1 2, María Teresa Hermida-Romero 1, Ana Reguera-Arias 1, Rosario García-Campelo 3, Mercedes de la Torre-Bravos 4, ángel Concha

            We studied the role of EGFR and other driver mutations in their involvement in acquired resistance to treatment with EGFR-TKIs and we analyzed the role of liquid biopsy as a non-invasive diagnostic method. Our results showed that liquid biopsy is a very useful tool monitoring the evolution of the disease and the resistance to TKIs. The detection of other concomitant mutations in driver genes is also key in this regard, so we found that alterations in the NFI tumor suppressor gene could be playing a role in disease progression and resistance to targeted therapies.

            Cancers (Basel). 2022 Jul 7;14(14):3323. 

            Efficacy and safety of selpercatinib in Chinese patients with advanced RET fusion-positive non-small-cell lung cancer: a phase II clinical trial (LIBRETTO-321)
            Shun Lu 1, Ying Cheng 2, Dingzhi Huang 3, Yuping Sun 4, Lin Wu 5, Chengzhi Zhou 6, Ye Guo 7, Jingxin Shao 8, Wanli Zhang 8, Jianying Zhou

            Selpercatinib, with potent and durable antitumor activity including intracranial activity, was well tolerated in Chinese patients with RET fusion-positive NSCLC, consistent with LIBRETTO-001 (ClinicalTrials.gov: NCT04280081).

            Ther Adv Med Oncol. 2022 Jul 28;14:17588359221105020. 

            High Expression of CUL9 Is Prognostic and Predictive for Adjuvant Chemotherapy in High-Risk Stage II and Stage III Colon Cancer
            Peng Zheng 1 2, Yang Lv 1 2, Yihao Mao 1 2, Feifan Shen 2 3, Zhiyuan Zhang 1 2, Jiang Chang 1 2, Shanchao Yu 2 3, Meiling Ji 1 2, Qingyang Feng 1 2, Jianmin Xu

            This retrospective study evaluated the clinical implications of CUL9 expression on the prognosis and the predictive value for postoperative adjuvant chemotherapy in consecutive patients with colon cancer. 

            Cancers. 2022 Aug 9;14(16):3843. 

            Using combined CT-clinical radiomics models to identify epidermal growth factor receptor mutation subtypes in lung adenocarcinoma
            Ji-Wen Huo 1, Tian-You Luo 1, Le Diao 2, Fa-Jin Lv 1, Wei-Dao Chen 2, Rui-Ze Yu 2, Qi Li 1

            Combined models that incorporate radiomics signature, clinical,and CT morphological features may serve as an auxiliary tool to predict EGFRmutation subtypes and contribute to individualized treatment for patients with LADC.

            Front Oncol. 2022 Aug 18;12:846589.


                1. <nobr id="heyne"></nobr>
                    <nobr id="heyne"></nobr>

                    <form id="heyne"><th id="heyne"></th></form>